ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
US Tech 100
17,163.60
1.09%
Dow Jones
38,085.80
-0.98%
Brent Oil
88.115
-0.04%
Bitcoin
64,400.18
-0.13%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Merus NV (MRUS) Quote

Merus NV

Merus NV (MRUS)

NASDAQ
44.93
2.96
(7.05%)
Closed April 25 4:00PM
Delayed by 15 minutes
44.93
0.00
( 0.00% )
Pre Market: 4:00AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
44.93
Bid
45.00
Ask
45.80
Volume
-
0.00 Day's Range 0.00
18.21 52 Week Range 52.035
Market Cap
-
Previous Close
44.93
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
616,367
Shares Outstanding
57,878,284
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Merus NV

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector
Gen Med & Surgical Hospitals
Industry
Gen Med & Surgical Hospitals
Website
www.merus.nl
Headquarters
Utrecht, Utrecht, Nld
Founded
1970
Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $44.93. Over the last year, Merus NV shares have traded in a share price range of $ 18.21 to $ 52.035.

Merus NV currently has 57,878,284 shares outstanding.

MRUS Latest News

More News

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...

April 08 2024
GlobeNewswire Inc.

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

April 03 2024
GlobeNewswire Inc.

Form 8-K - Current report

March 06 2024
Edgar (US Regulatory)

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

– Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics Resulting from the Collaboration – Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a...

March 06 2024
Business Wire

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

March 05 2024
GlobeNewswire Inc.

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

March 04 2024
GlobeNewswire Inc.

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

February 28 2024
Edgar (US Regulatory)

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial -   Petosemtamab in 2L+ HNSCC phase 3 trial...

February 28 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
14.3710.774161735740.5645.66539.2794710642.44295439CS
4-0.52-1.1441144114445.4546.5639.2759391142.72148323CS
129.125.39771141535.8352.03535.0661636744.38082932CS
2624.63121.33004926120.352.03519.80552283236.88703925CS
5224.73122.42574257420.252.03518.2142369331.40849949CS
15621.3290.300720033923.6152.03512.0335074426.02543049CS
26028.58174.80122324216.3552.03510.1824942624.61589294CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TVGNTevogen Bio Holdings Inc
$ 1.62
(90.59%)
195.75k
PEGYPineapple Energy Inc
$ 0.0785
(51.25%)
2.76M
BCSAUBlockchain Coinvestors Acquisition Corporation I
$ 16.71
(48.53%)
2
COMMCommScope Holding Company Inc
$ 1.18
(29.00%)
5
FRGTFreight Technologies Inc
$ 1.16
(26.96%)
25.7k
IDAIT Stamp Inc
$ 0.088
(-88.42%)
995
ACONAclarion Inc
$ 0.31
(-21.06%)
27.12k
WORXSCWorx Corporation
$ 2.25
(-18.48%)
430
PCSAProcessa Pharmaceuticals Inc
$ 2.03
(-16.46%)
15.34k
VINCVincerx Inc
$ 0.765
(-14.69%)
874
PEGYPineapple Energy Inc
$ 0.0785
(51.25%)
2.77M
SQQQProShares UltraPro Short QQQ
$ 11.61
(-3.25%)
199.6k
TVGNTevogen Bio Holdings Inc
$ 1.62
(90.59%)
196.43k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 7.56
(3.00%)
89.83k
FFIEFaraday Future Intelligent Electric Inc
$ 0.0477
(-2.65%)
81.56k

MRUS Discussion

View Posts
Phosphene Phosphene 3 years ago
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

https://www.globenewswire.com/news-release/2020/10/12/2107078/0/en/Merus-and-myTomorrows-Announce-Expansion-of-Collaboration-for-Screening-and-eNRGy-Clinical-Trial-Awareness-for-Cancer-Patients-with-Neuregulin-1-Fusion-Tumors.html
👍️0
Phosphene Phosphene 4 years ago
The Baker Brothers have 7% ownership.

https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
👍️0
Phosphene Phosphene 4 years ago
Board Member: Victor Sandor

https://ir.merus.nl/board-member/victor-sandor

https://www.businesswire.com/news/home/20200824005127/en/Prelude-Therapeutics-Announces-Closing-50M-Series-Financing
👍️0
Phosphene Phosphene 4 years ago
Second Quarter 2020 Results:

https://www.globenewswire.com/news-release/2020/08/06/2074649/0/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-and-Provides-Business-Update.html
👍️0
Phosphene Phosphene 4 years ago
https://merus.nl/
👍️0
Phosphene Phosphene 4 years ago
European cancer biotech Merus nabs Sanofi I-O chief Andrew Joe

https://www.fiercebiotech.com/biotech/european-cancer-biotech-merus-nabs-sanofi-i-o-chief-andrew-joe
👍️0

Your Recent History

NASDAQ
MRUS
Merus NV
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved